Ensayos Clínicos Cabeza y Cuello abiertos a reclutamiento (Actualizado enero 2021)

Fuente de información: Clinical trials.gov; EU Clinical Trials Register; REEC (AEMPS)

EudraCT-Number	NCT	CODIGO_ESTUDIO	TITULO_ESTUDIO	FASE	INDICACION	ESTADO	MEDICACION	CENTROS	PROMOTOR	ESPECIALIDAD
ENSAYOS PROMOVIDOS POR TTCC										
2019-002922-60	4282109	TTCC2019-01/CA209-7HE (NIVOTAX)	Phase II Multicenter Randomized Trial to Assess the Efficacy and Safety of First Line Nivolumab in Combination With Paclitaxel in Subjects With R/M HNSCC Unable for Cisplatin-based Chemotherapy (NIVOTAX). 1ºLINEA recurrent/metastatic	Phase II	Patients unable for cisplatin-based chemotherapy	RECLUTANDO	NIVOLUMAB	ICO_Hospitalet (BCN) H.U.Clinic (BCN) ICO_Badalona (BCN) ICO_Girona (BCN) H.Clinico (Madrid) H 12 Octubre (Madrid) H.U.La Fe (Valencia) H.U.Miguel Servet C.H.Navarra H.C.L.Blesa(Zaragoza) H.U.V.Rocio (Sevilla) H.Regional (Malaga) H.Clinico Valencia H.U.V.Nieves (Granada) H.U.V.Salud (Toledo) C.H.Salamanca C.O.Galicia(Coruña) H.U.Donosti(S.Sebastian) H.U.M.Valdecilla. H.U.Lucus Augusti(Lugo)	TTCC	Oncologia_medica
N.A	4672772	TTCC-2019-02 (ERBITAX)	Retrospective Study With Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN (Squamous Cell Carcinoma of the Head and Neck): Real World Data	RETROSPECTIVE	The main objective will be to estimate the Progression-free survival (PFS) in patients treated with paclitaxel 80 mg/m2 as a starting dose, with weekly cetuximab that could have been switched to biweekly during the maintenance phase, as first line for recurrent and/or metastatic SCCHN.	RECLUTANDO	Cetuximab Paclitaxel	ICO_Hospitalet (BCN) H del Mar (BCN) ICO_Badalona (BCN) ICO_Girona (BCN) H.Clinico (Madrid) H 12 Octubre (Madrid) H.U.La Fe (Valencia) H.U.M. Servet(Zaragoza) C.H.Navarra (Pamplona) H.U.V.Valme (Sevilla) H.R.Universitario (Malaga) H.U.Lucus Augusti (Lugo) H.U.V.Nieves (Granada) H.U.V.Salud (Toledo) C.H.Salamanca C.O.Galica(Coruña) H.U.G.Marañón (Madrid)	TTCC	Oncologia_medica
Otros PROMOTORES										
2017-001139-38	3765918	MK3475-689	Estudio de fase III, aleatorizado y abierto para evaluar pembrolizumab como tratamiento neoadyuvante y en combinación con la asistencia habitual como tratamiento adyuvante en el carcinoma epidermoide de cabeza y cuello locorregionalmente avanzado (CECC LA), extirpable, en estadio III-IVA.	Phase III	carcinoma epidermoide de cabeza y cuello locorregionalmente avanzado (CECC LA), extirpable , en estadio III-IVA	RECLUTANDO	Pembrolizumab Cisplatin	H.U.de Santiago H.U.La Paz (Madrid) H.U.V.Rocio (Sevilla) ICO-Hospitalet (BCN) ICO-Badalona (BCN) H.U.Vall d´Hebron (BCN)	Merck-Sharp & Dohme Corp.	Oncologia_medica N=704
2019-003717-34	4199104	MK-7902-010	A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010).	Phase III	This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma.ECOG:0-1	RECLUTANDO	Pembrolizumab Lenvatinib	ICO_Hospitalet (BCN) H.U.Vall d´Hebron (BCN) H.U 12 Octubre (Madrid) H.U.La Paz (Madrid) H.U.L. Blesa (Zaragoza) H.U.V.de Valme (Sevilla)	Merck Sharp & Dohme Corp.	Oncologia_medica N=500
2018-001437-40	3719690	KO-TIP-007	El estudio AIM-HN y SEQ-HN: Estudio pivotal no comparativo de 2 cohortes para evaluar la eficacia de tipifarnib en pacientes con carcinoma de células escamosas de cabeza y cuello (CCECC) con mutaciones de HRAS (AIM-HN) y el impacto de las mutaciones de HRAS en la respuesta a las terapias sistémicas de primera línea para el CCECC (SEQ-HN).	Phase II	Carcinoma de células escamosas de cabeza y cuello (CCECC) recurrente o metastásico con mutaciones en HRAS	RECLUTANDO	Tipifarnib (oral)	H.Vall d´Hebron (BCN) H.U.Clinic (BCN) H.U. Sant Pau (BCN) ICO_Hospitalet (BCN) H.del Mar (BCN) H La Paz (Madrid) H 12 Octubre (Madrid) H.U.Sanchinarro(Madrid) H.U.La Fe (Valencia) H.U.M.Servet (Zaragoza) C.H.Navarra (Pamplona) H.U.Santiago de Compostela H.U.V.Rocio (Sevilla) H.U.V.Victoria (Malaga)	Kura_Oncology, Inc	Oncologia_medica
2019-003060-42	4220866	1454-002	A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination With IV Pembrolizumab vs IV Pembrolizumab Monotherapy	Phase II	The purpose of this study is to assess the efficacy and safety of intratumoral (IT) MK-1454 in PLUS pembrolizumab (MK-3475) compared to pembrolizumab alone as a first line treatment of adults with metastatic or unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).	RECLUTANDO	MK-3475	H.U.Vall d´Hebron (BCN) H.Clinic (BCN) H.U.Ramon y Cajal(Madrid) H.U.V. Victoria (Málaga)	Merck Sharp & Dohme Corp.	Oncologia_medica
2019-002263-99	4128696	209229	A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Phase II/III	Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3)	RECLUTANDO	GSK3359609 & Pembrolizumab & Placebo	H.U.Clinic(BCN) H.U.Vall d´Hebron (BCN) ICO_Hospitalet (BCN) H.U.V.Victoria(Malaga) H.U.G.Marañon(Madrid) H.U.Ramon y Cajal (Madrid) H.U.La Paz (Madrid) H.U.Quiron (Madrid) H.U.M. Servet (Zaragoza) H.U.Santiago de Compostela H.Clinico Valencia C.H.Navarra	GlaxoSmithKline & Merck Sharp & Dohme Corp.	Oncologia_medica
2019-000569-19	4428151	MK-7902-009	A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009) 2ªLinea añade Lenva a PD a Inmunoterapia.	Phase II	Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) which has progressed after treatment with both platinum therapy and most recently immunotherapy	RECLUTANDO	Pembrolizumab Lenvatinib	ICO-Hospitalet (BCN) H.General Valencia H.U.Vall d´Hebron(BCN) H.U.Ramon y Cajal (Madrid) H.U.V. Victoria (Málaga)	Merck Sharp & Dohme Corp.	Oncologia_medica
2018-002513-36	3769506	ASP-1929-301	A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician´s Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy	Phase III	Locoregional, recurrent head and neck squamous cell carcinoma	RECLUTANDO	ASP-1929 Photoimmunotherapy	H.U.Sanchinarro (Madrid) H.U.Vall d´Hebron (BCN)	Rakuten Aspyrian, Inc	Oncologia_medica
2019-004770-25	4590963	D7310C00001	A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor	Phase III	This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in patients with recurrent or metastatic head and neck cancer.	Not yet recruiting (20/01/21)	Monalizumab Cetuximab	6 Centros	AstraZeneca	Oncologia_medica
2019-002745-38	4529850	GTI-4419-202	An Open Label Multi-Center Study of the Effects of Superoxide Dismutase Mimetic GC4419 When Administered to Reduce the Incidence and Severity of Severe Oral Mucositis (SOM) Associated With Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer	Phase II	GTI-4419-202 is a Phase 2 open-label study of the effects of GC4419 when administered IV in combination with IMRT/cisplatin to up to 70 subjects with head and neck cancer, who are at high risk for SOM.	RECLUTANDO	GC4419	C.H.Navarra H.U.Vall d´Hebron(BCN) H.U.Ramon y Cajal H.U.12 Octubre(Madrid) H.U.Cruces (Barakaldo) H.U.Fuenlabrada (Madrid) C.U.Salamanca H.U.V.Rocio (Sevilla) H.U.Sanchinarro (Madrid) ICO_Girona	Galera Therapeutics, INC	Oncologia Médica/Radioterapica
2018-000789-13	3669718	ISA101B-HN-01-17	Estudio de fase II, aleatorizado, con doble enmascaramiento y controlado con placebo de cemiplimab en comparación con la combinación de cemiplimab más ISA101b en el tratamiento de sujetos con cáncer orofaríngeo (COF) VPH16 -positivo resistente al platino	Phase II	Cáncer orofaríngeo (COF) VPH-16 positivo resistente al platino	RECLUTANDO	Human Papilloma Virus (HPV) type 16 E6/E7 synthetic long peptide (SLP®) vaccine	ICO-Hospitalet (BCN) H.U.12-Octubre (Madrid) H.C.San Carlos (Madrid) H.U.SanChinarro(Madrid) H.U.La Paz (Madrid) H.U.Clinic (BCN) H.U.Vall d´Hebron(BCN) H.U.Salamanca H.U.V.Victoria(Malaga)	ISA-Therapeutics B.V	Oncologia_medica
2018-001095-38	3799744	ICO-VCN-H&N_2018	A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck	Phase I	Metastasis & Recurrence	RECLUTANDO	Genitic:VCN-01 Biological: Durvalumab	ICO_Hospitalet (BCN) H.U.Vall d´Hebron(BCN)	ICO *Collaborators:* VCN Biosciences S.L BioClever 2005 S.L Astra Zeneca	Oncologia_medica N= 20

EudraCT-Number	NCT	CODIGO_ESTUDIO	TITULO_ESTUDIO	FASE	INDICACION	ESTADO	MEDICACION	CENTROS	PROMOTOR	ESPECIALIDAD
2019-003167-22	4196283	M19-894	A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Phase I	The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).	RECLUTANDO	ABBV-368 Tilsotolimod D Nab-paclitaxel ABBV-181	H.Clinic (BCN) ICO-Hospitalet (BCN) H.U.12 Octubre (Madrid) Start_Sanchinarro(Madrid) H.U.V.Victoria (Málaga) H.Clínico (Valencia) H.U.Fuenlabrada (Madrid)	AbbVie / Idera Pharmaceuticals, Inc	Oncología_medica
2019-003167-22	4196283	M19-894	A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Phase I	The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).	RECLUTANDO	ABBV-368 Tilsotolimod Nab-paclitaxel ABBV-181	H.U.Clinic (BCN) H.U.Fuenlabrada (Madrid) H.U.12 Octubre (Madrid) Start_Sanchinarro (Madrid) H.U.V. Victoria (Málaga)	AbbVie	Oncología_medica
Tumores Sólidos con Cohorte de Cancer de Cabeza y Cuello										
2018-001608-12	3645928	IOV-COM-202	Estudio Fase II, multicentrico de linfocitos de tumores autologos (LN-144 o LN-145)en pacientes con SOLID TUMORS.	Phase II	Tumores sólidos incluyendo melanoma metastásico avanzado (MM) o irresecable, **carcinoma epidermoide de cabeza y cuello avanzado (CECC)** y cáncer de pulmón no microcítico (CPNM) . 1ªLINEA o SUCESIVAS	RECLUTANDO	Proleukin Pembrolizumab	H.U.Vall d´Hebron (BCN) ICO-Duran i Reynals (BCN) H.U.12 Octubre (Madrid) H.U.SanChinarro (Madrid) H.U.G.Marañon (Madrid) F.J.Diaz(Madrid) H.R.U.Málaga H.U.Valdecilla (Santander)	Iovance Biotherapeutics.Inc	Oncología_medica
2017-005076-26	3485209	SGNTV-001	Open label phase 2 study of Tisotumab Vedotin for locally advanced or metastatic disease in SOLID TUMORS.	Phase II	4 _COHORTS: Colorectal , NSCLC, Exocrino pancreatic adenocarcinoma and SCCHN	RECLUTANDO	Tisotumab vedotin	H.Vall d´Hebron (BCN) H.U.Ramon y Cajal (Madrid) H.U.Sanchinarro (Madrid) H.Quironsalud (BCN) ICO_Badalona (BCN)	Seattle Genetics, Inc	Oncología_medica
2017-000241-49	3207867	CNIR178X2201	A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma	Phase II	NSCLC, Non Small Cell Lung Cancer RCC, Renal Cell Cancer Pancreatic Cancer Urothelial Cancer Head and Neck Cancer DLBCL, Diffused Large B Cell Lymphoma MSS, Microsatellite Stable Colon Cancer TNBC, Triple Negative Breast Cancer Melanoma	RECLUTANDO	NIR178 & PDR001	H.U.Vall d´Hebron(BCN)	Novartis Pharmaceuticals	Oncología_medica
2015-003385-84	2568267	GO40782 (RXDX-101-02)	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Phase II	Breast Cancer, Cholangiocarcinoma Colorectal Cancer, Head and Neck Neoplasms Lymphoma, Large-Cell, AnaplasticMelanoma ,Neuroendocrine, Tumors Non-Small Cell Lung, CancerOvarian Cancer Pancreatic, CancerPapillary Thyroid, CancerPrimary Brain TumorsRenal Cell Carcinoma Sarcomas,Salivary Gland Cancers Adult Solid Tumor	RECLUTANDO	ENTRECTINIB	H.U.Vall d´Hebron (BCN) H.U.12 Octubre (Madrid) H.U.Ramon y Cajal (Madrid) START Sanchinarro (Madrid) H.U.V.Victoria (Malaga) H.C.U.San Carlos (Madrid) H.U.Virgen Rocio (Sevilla)	Hoffmann-La Roche/ Ignyta, Inc	Oncología_medica
2017-003182-94	3386721	BP40234	An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of RO6874281, an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-A (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors	Phase II	Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers	RECLUTANDO	RO6874281 Atezolizumab Gemcitabine Vinorelbine	Clínica U.Navarra Hospital del Mar (BCN) H.U. Vall d'Hebron (BCN) START_ F. Jimenez Diaz START_ Sanchinarro	Hoffmann-La Roche	Oncología_medica
2018-001994-25	3625323	TACTI-002(PO1S KEYNOTE-PN798	TACTI-002 (Two ACTive Immunotherapeutics): A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurrent PD-X refractory NSCLC or with recurrent or metastatic squamous head and neck cancer (HNSCC) receiving the soluble LAG-3 fusion protein eftilagimod alpha (IMP321) in combination with pembrolizumab (PD-1 antagonist)	Phase II	Recurrent or metastatic squamous head and neck cancer (HNSCC)	RECLUTANDO	IMP321 Pembrolizumab	H.Santa Creu i Sant Pau ICO-Badalona (BCN) H.U.Vall d´Hebron(BCN) F.J.Diaz (Madrid)	IMMUTEP S.A.S	Oncología_medica
2015-003582-28	2576431	LOXOTRX-15002 (NAVIGATE)	A Phase 2 Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects With NTRK Fusion-positive Tumors	Phase II	The primary objective of this study is to investigate the efficacy of larotrectinib for the treatment of advanced solid tumors harboring a fusion of neurotrophic tyrosine receptor kinase (NTRK) of types 1-3 in **children and adults.** ARM B H&N: Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles,	RECLUTANDO	Larotrectinib (LOXO-101)	H.U.Vall d´Hebron(BCN) H.U.Sanchinarro(Madrid) F.Jimenez Diaz (Madrid) H.U. Valdecilla(Santander) H.General de Valencia	Bayer	Oncología Medica N= 203 **12 years and older**
2015-004535-12	2383927	KO-TIP-001	An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations	Phase II	Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)HRAS Mutant Tumor. Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor	NO RECLUTANDO	Tipifarnib (oral)	H.U.Vall d´Hebron (BCN) START.Sanchinarro(Madrid)	Kura_Oncology, Inc	Oncología_medica
2018-003402-63	3917381	GCT1046-01	First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors	Ph1, first-in-human (FIH) and an expansion part (phase 2a)	The trial is an open-label, multi-center safety trial of GEN1046. The trial consists of two parts, a dose escalation part (phase 1, first-in-human (FIH) and an expansion part (phase 2a)). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined	RECLUTANDO	GEN1046	Clínica.U.de Navarra H.U.Vall d´Hebron (BCN) START-FJD(Madrid) START_Sanchinarro.Madrid H.Clínico de Valencia H.U.12 Octubre (Madrid)	Genmab A/S	Oncología_medica
2019-003998-26	4424641	GCT1044-01	First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1044 in Subjects With Malignant Solid Tumors	First in human	The trial is an open-label, multi-center safety trial of GEN1044. The trial consists of two parts: a dose escalation part (phase 1) and an expansion part (phase 2a). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined from phas	RECLUTANDO	Biological: GEN1044 (is an IgG1 bispecific antibody targeting CD3 and ST4).	H.Vall d´Hebron (BCN) START_F. J.Diaz (Madrid)	Genmab/AbbVie	Oncología_medica
2016-002219-16	2988960	M15-862	A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumor	Phase I	Advanced, solid tumors, squamous cell cancer of the head and neck, pancreatic cancer, non-small cell lung cancer, melanoma	RECLUTANDO	ABBV-927 & ABBV-181	START_Sanchinarro.Madrid H.U.P. de Hierro (Madrid) H.U.La Fé (Valencia) START_F. J.Diaz (Madrid)	AbbVie	Oncología_medica
2019-000446-36	3894618	SL01-DEL-101	Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas	Phase I	Squamous Cell Carcinoma of the Head and Neck, MelanomaNon Small Cell Lung CancerUrothelial CarcinomaGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaSquamous Cell Carcinoma of the AnusSquamous Cell Carcinoma of the CervixSquamous Cell Carcinoma of the SkinRenal Cell CarcinomaHodgkin LymphomaDiffuse Large B Cell LymphomaMismatch Repair Deficient or MSI-High Solid Tumors	RECLUTANDO	SL-279252	H.U.Vall d´Hebron (Barcelona)	Shattuck Labs, Inc.	Oncología_medica
UK	1351103	CLGK974X2101	A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands	Phase I	This primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies for whom no effective standard treatment is available.	RECLUTANDO	Drug:LGK974 Biological: PDR001	2 Sites Barcelona 2 Sites Madrid	Novartis Pharmaceuticals	Oncología_medica
2018-004334-15	4234113	SC103	A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors	Phase I	HNSCC & Thyroid, A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors	RECLUTANDO	SO-C101 Pembrolizumab	H.U.Vall d´Hebron(BCN)	SOTIO	Oncología_medica
2016-003429-41	3291002	CV-8102-008	Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinom	Phase I	This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.	RECLUTANDO	Biological: CV8102 Biological: CV8102 + anti-PD-1 therapy	H.U.Vall d´Hebron (BCN) H.U.V.Victoria (Málaga)	CureVac AG / Syneos Health	Oncología_medica

EudraCT-Number	NCT	CODIGO_ESTUDIO	TITULO_ESTUDIO	FASE	INDICACION	ESTADO	MEDICACION	CENTROS	PROMOTOR	ESPECIALIDAD
2019-004748-31	4254107	SGNTGT-001	A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies	Phase I	Part C will study how well SEA-TGT with pembrolizumab works to treat solid tumors. Pembrolizumab is a drug that can be used to treat these types of cancer.	RECLUTANDO	SEA-TGT Pembrolizumab	H.Vall d´Hebron (BCN)	Seagen Inc.	Oncología_medica
2017-001475-23	3289962	GO39733	A phase 1a/1b, open-label, dose escalation study of the safety and PKs of RO7198457 as a single agent and in combination with Atezolizumab in patients with locally advanced or metastatic Tumors.	Phase Ia/Ib	8_COHORTS: Melanoma, Bladder Ca, NSCLC, Colorectal, Triple Negative Breast Ca, Renal Ca, H&N Cancer , other Solid Cancers.	RECLUTANDO	Atezolizumab RO7198457	H.U.Vall d´Hebron (BCN) C.U.Navarra(Pamplona)	Genentech,Inc	Oncología_medica
2017-001553-14	3150810	BGB-290-103	A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors	Phase Ib	he primary objective of this study is to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2 dose (RP2D) and schedule of pamiparib in combination with TMZ, and to determine the antitumor activity of pamiparib in combination with TMZ.	RECLUTANDO	Pamiparib Temozolomide	H.Vall d´Hebron (BCN) ICO-Hospitalet (BCN) Start_F.J. Diaz (Madrid) Start_Sanchinarro (Madrid) H.Clinico (Valencia)	BeiGene	Oncología_medica
2018-001456-34	3543813	CTMX-M-2029-001	A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)	Phase I/II	The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced unresectable solid tumors or diffuse large B-cell lymphoma (DLBCL). PROCLAIM: PRObody CLinical Assessment In Man CX-2029 clinical trial 001	RECLUTANDO	CX-2029	H.Clinic(BCN) H.U.La Paz (Madrid) Start_Sanchinarro (Madrid)	CytomX Therapeutics	Oncología_medica
2018-004771-12	4000529	CTNO15SB12101	A Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies	Phase Ib	This study is a Phase Ib, multi-center, open-label study of TNO155 in combination with spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors.	RECLUTANDO	TNO155 Spartalizumab Ribociclib	H.Vall d´Hebron (BCN)	Novartis Pharmaceuticals	Oncología_medica
2016-001860-12	2900651	CMAK683X2101	A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies	Phase I/II	H&N cancer subjects who have radiographically progressed during or following prior platinum-containing chemotherapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.	RECLUTANDO	MAK683	H.U.12 Octubre (Madrid)	Novartis Pharmaceuticals	Oncología_medica
2019-000478-45	3893955	M19-037	A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors	Phase I	Advanced Solid, TumorsTriple-Negative Breast Cancer (TNBC),Non-small-cell-lung-cancer (NSCLC),Head and Neck Squamous Cell Carcinoma (HNSCC), Metastatic Solid Tumors	Not yet recruiting (01/10/20)	ABBV-927 ABBV-368 ABBV-181 Docetaxel	H.Vall d´Hebron (BCN) START_F.J.Diaz (Madrid) START_Sanchinarro(Madrid)	AbbVie	Oncología_medica
2020-000075-20	4465487	R6569-ONC-1933	A Phase 1 Study of REGN6569, an Anti-GITR mAb, With Cemiplimab in Patients With Advanced Solid Tumor Malignancies	Phase I	For dose escalation cohorts, the primary objective is to evaluate the safety and tolerability of REGN6569 as monotherapy lead-in and in combination with cemiplimab.	Not yet recruiting (20/01/21)	REGN6569 Cemiplimab	4Centros Madrid 2Centros Barcelona	Regeneron Pharmaceuticals	Oncología_medica
UK	4504669	D995OC00001	A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvalumab (MEDI4736) in Participants With Advanced Solid Tumours.	Phase I	The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with Select Advanced Solid Tumors	Not yet recruiting (20/01/21)	AZD8701	1 Site Barcelona 1 Site Pamplona	AstraZeneca	Oncología_medica
2019-003474-35	3138889	16-214-05	A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Phase I/II	This study is to assess the safety and tolerability, and to assess the preliminary clinical benefit of NKTR-214 when combined with pembrolizumab (KEYTRUDA®).	Not yet recruiting (20/01/21)	NKTR-214 Pembrolizumab	7 Sites	Nektar Therapeutics	Oncología_medica
2018-001146-34	3260322	8374-CL-0101	A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Phase I	Advanced and serious forms of cancers such as head and neck cancers, non-small cell lung cancers, prostate cancer, ovarian cancer, colorectal cancer and gastric cancer	NO RECLUTANDO	ASP8374 Pembrolizumab	H.U.Clinic(BCN) H.U.Vall d´Hebron (BCN) ICO_Hospitalet (BCN) Start Sanchinarro(Madrid) Start_F.J.Diaz (Madrid) H.del Mar(BCN) H.U.V.Victoria(Malaga) H.U.V.Rocio(Sevilla) H.U.G.Marañon(Madrid)	Astellas Pharma Global Development INC Astellas.	Oncología_medica
2016-002799-28	3260023	TG4001.12	A phase Ib/II trial evaluating the combination of TG4001 and avelumab in patients with HPV-16 positive recurrent or metastatic malignancies and expansion cohort to oropharyngeal squamous cell carcinoma of the head and neck (SCCHN)	Phase Ib/II	HPV-16 positive recurrent or metastatic malignancies including oropharyngeal squamous cell carcinoma of head and neck, cervical cancer, vulvar cancer, vaginal cancer, penile cancer, anal cancer	NO RECLUTANDO	TG4001 Avelumab	H.U.12 Octubre (Madrid) H.U.Clinico (Madrid) ICO_Badalona (BCN) H.U.V.Victoria (Malaga) H.U.V.Nieves (Granada) H.U.General d Valencia	TRANSGENE	Oncología_medica
UK	4261179	2019-003825-56	An Exploratory Prospective, Open-label, Unicentric Study With Cross-over Design, Comparing Lymphoseek® vs. Albumin Nanocolloid for Image- Guided Sentinel Lymph Node Mapping in Head and Neck, Melanoma and Breast Cancer.(SENTINELSEEK)	Phase IV	Comparison of the concordance of albumin nanocolloid and Lymphoseek® in the detection of lymph nodes of primary and secondary stage drainage by performing two lymphogammagrams	Not yet recruiting (01/10/20)	Lymphoseek Nanocoll	H.U.Clinic (BCN)	Fundacion Clinic per a la Recerca Biomédica	Oncología_medica
UK	4145180	0045-N-16	Effectiveness of a Physical Recovery Program for Head and Neck Cancer Patients (3C-CUIDATE)	Prospectivo	This project intends to carry out an experimental randomized controlled study with 84 patients treated of head and neck cancer who will be assigned randomly to the study groups: a) manual therapy program or, b) control group. The assessment refers to a baseline form (at the beginning of the study), at 6 weeks and at 6 months of patient follow-up.	RECLUTANDO	Manual therapy	Universidad de Granada	Universidad de Granada	Oncología
UK	4110977	RAREST-02	RAdiotherapy RElated Skin Toxicity: A Reminder App to Reduce Radiation Dermatitis Rates in Patients With Head-and-Neck Cancer	UK	The goal of this trial is to investigate whether the addition of a reminder app to standard care leads to a reduction of dermatitis and oral mucositis during radio(chemo)therapy for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN).	RECLUTANDO	Mobile application (reminder app)	H.U.de Cruces (Bilbao) H.U.La Fe(Valencia)	University Hospital Schleswig-Holstein	Oncología_radioterápica
2018-003352-20	3768063	BO40729	An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)	Phase IV	Squamous cell carcinoma of head and neck, Solid Tumors, NSCLC, Urothelial carcinoma, Renal cell carcinoma	RECLUTANDO	Atezolizumab	C.U.Navarra H.U.Sanchinarro (Madrid) H.Sabadell (BCN)	Hoffmann-La Roche	Oncología_medica